- WACKER acquired ADL BioPharma for over €100 million.
- The acquisition adds 2,000 cubic meters of fermentation capacity.
- WACKER aims to generate €1 billion in sales by 2030.
- ADL BioPharma employs roughly 300 staff.
Acquisition Details
WACKER, headquartered in Munich, has acquired 100% of ADL BioPharma from Kartesia. This acquisition, valued at over €100 million, includes the entire site in León, Spain, expanding WACKER’s fermentation capacities by approximately 2,000 cubic meters (gross volume).
Strategic Importance
WACKER’s CEO, Christian Hartel, emphasized that this acquisition is crucial for the growth of their biotechnology business, with a target to generate €1 billion in sales by 2030. The additional fermentation capacities will support the production of sustainably produced dietary ingredients.
Operational Expansion
WACKER BIOSOLUTIONS has operated fermentation plants at the León site since 2016, initially acquiring 800 cubic meters of fermentation capacity from ADL BioPharma. The acquisition has led to significant upgrades and the creation of 60 new jobs, quadrupling the number of employees at the site.
Future Plans
Susanne Leonhartsberger, head of WACKER BIOSOLUTIONS, stated that ADL BioPharma’s CMO business aligns well with WACKER’s portfolio. The company plans to integrate these activities into WACKER BIOSOLUTIONS, focusing on sustainable ingredients for the food and nutritional supplements industries, and foresees growth opportunities at the León site in the coming years.
